Stockscreener 앱 받기
1.33
5.56%
0.07
시장 영업 전:
1.33
전일 마감가:
$1.26
열려 있는:
$1.24
하루 거래량:
897.97K
Relative Volume:
0.44
시가총액:
$94.04M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-0.3317
EPS:
-4.01
순현금흐름:
$-113.02M
1주 성능:
+7.26%
1개월 성능:
+9.02%
6개월 성능:
-21.30%
1년 성능:
-66.83%
1일 변동 폭
$1.24
$1.365
1주일 범위
$1.225
$1.365
52주 변동 폭
$0.8719
$4.59
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
BMEA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.33 | 89.09M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Will Biomea Fusion Inc. stock return to pre crisis levels2026 world cup usa national team round of 16 key players build up play expert forecast preview - ulpravda.ru
Biomea Fusion looks to major milestones in 2026 - Traders Union
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Biomea Fusion Inc. (BMEA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion explores challenges of insulin therapy - Traders Union
Can Biomea Fusion Inc. stock outperform in 2025 bull marketCEO Change & Detailed Earnings Play Strategies - Улправда
Published on: 2025-12-20 18:19:39 - Улправда
How interest rate cuts could boost Biomea Fusion Inc. stockWeekly Stock Recap & Daily Momentum Trading Reports - Улправда
Published on: 2025-12-20 15:52:57 - Улправда
Is Biomea Fusion Inc. stock near bottom after declineJuly 2025 Retail & Weekly Hot Stock Watchlists - DonanımHaber
Will Biomea Fusion Inc. stock split attract more investors2025 Technical Overview & Technical Entry and Exit Alerts - DonanımHaber
Published on: 2025-12-19 02:18:12 - Улправда
Aug Closing: Will Biomea Fusion Inc. stock outperform growth indexesJuly 2025 Action & Risk Controlled Swing Alerts - Улправда
Gap Down: Can Biomea Fusion Inc. stock outperform in 2025 bull market - Улправда
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from NASDAQ Biotechnology Index - marketscreener.com
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Insider Buying: Biomea Fusion (NASDAQ:BMEA) Insider Acquires 30,000 Shares of Stock - MarketBeat
Biomea Fusion Director Rainer M Erdtmann Acquires 30,000 Shares - TradingView — Track All Markets
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea F - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025 - ts2.tech
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com Nigeria
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing By Investing.com - Investing.com South Africa
Biomea Fusion Presents Promising Results for Icovamenib in Treating Type 2 Diabetes at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Is Biomea Fusion Inc. stock a buy before product launchesEarnings Recap Report & Weekly Top Gainers Alerts - Newser
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway - TradingView — Track All Markets
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView — Track All Markets
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):